Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.70
Bid: 14.00
Ask: 14.70
Change: -1.10 (-7.12%)
Spread: 0.70 (5.00%)
Open: 14.00
High: 14.00
Low: 13.70
Prev. Close: 15.45
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

8 Nov 2016 18:25

RNS Number : 6778O
Oncimmune Holdings PLC
08 November 2016
 

8 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Percentage of issued share capital (%)

Meinhard Schmidt

Non-executive Chairman

120,370

108

0.236

Geoffrey Hamilton-Fairley

Chief Executive Officer

528,273

1

1.035

119,875

108

0.235

Andrew Millet

Chief Financial Officer

92,593

108

0.181

Andrea Murray

Chief Operational Scientist

41,667

108

0.082

Maarten Brusse

Chief Commercial Officer

74,074

108

0.145

 

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

 

Non-Executive Chairman, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

120,370

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

120,370

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

528,273

N/A

119.875

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

648,148

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrew Millet

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

92,593

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

92,593

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrea Murray

2

Reason for the notification

a)

Position/status

 

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

41,667

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

41,667

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Maarten Brusse

2

Reason for the notification

a)

Position/status

 

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

74,074

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

74,074

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIBDBSDGBGLI
Date   Source Headline
21st Sep 20227:00 amRNSUnaudited results for the 12 months to 31 May 2022
30th Aug 20223:53 pmRNSRevised Notice of Results
15th Aug 20222:06 pmRNSHolding(s) in Company
8th Aug 202211:55 amRNSHolding(s) in Company
15th Jul 202210:44 amRNSHolding(s) in Company
13th Jul 20227:00 amRNSGrant of Options and PDMR Dealing
8th Jul 20227:00 amRNSBoard Changes and Trading Update
20th Jun 20222:19 pmRNSHolding(s) in Company
16th Jun 20229:59 amRNSHolding(s) in Company
7th Jun 202210:20 amRNSHolding(s) in Company
6th Jun 20229:30 amRNSHolding(s) in Company
1st Jun 20228:18 amRNSHolding(s) in Company
31st May 202212:41 pmRNSHolding(s) in Company
26th May 20229:57 amRNSHolding(s) in Company
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 202212:11 pmRNSHolding(s) in Company
18th May 202211:46 amRNSHolding(s) in Company
5th May 20225:32 pmRNSHolding(s) in Company
3rd May 20226:10 pmRNSHolding(s) in Company
26th Apr 20224:26 pmRNSHolding(s) in Company
21st Apr 20227:00 amRNSQueen’s Award for Enterprise in Innovation 2022
14th Apr 202212:24 pmRNSExercise of Options, PDMR Dealing and TVR
8th Apr 20227:00 amRNSTwo further ImmunoINSIGHTS contracts signed
4th Apr 20222:43 pmRNSHolding(s) in Company
29th Mar 20224:46 pmRNSExercise of Options, PDMR Dealing and TVR
18th Mar 20223:01 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSBlock Listing Six Monthly Return
15th Mar 20227:00 amRNSExercise of Warrants and Total Voting Rights
9th Mar 20224:08 pmRNSHolding(s) in Company
7th Mar 20222:10 pmRNSPDMR Dealing
7th Mar 20227:00 amRNSFollow-on contract to validate previous profiling
4th Mar 20227:00 amRNSImmunoINSIGHTS contract signed with global pharma
1st Mar 20227:00 amRNSImmunoINSIGHTS and Synexa partnership
28th Feb 20227:05 amRNSInterim Results
28th Feb 20227:00 amRNSContract signed with Verily Life Sciences
25th Feb 20227:00 amRNSNotice of Half Year Results
21st Feb 20223:14 pmRNSHolding(s) in Company
17th Feb 20227:00 amRNSEarlyCDT Lung approved and adopted in Aragon Spain
15th Feb 20227:00 amRNSImmunoINSIGHTS commercial update
31st Dec 20217:00 amRNSResults from COVID-19 autoantibody profiling panel
24th Dec 20217:00 amRNSPDMR Dealing
22nd Dec 202111:10 amRNSGrant of Options and PDMR Dealing
21st Dec 202111:34 amRNSPDMR Dealing
21st Dec 20217:00 amRNSImmunoINSIGHTS commercial update
20th Dec 20213:13 pmRNSTotal Voting Rights
7th Dec 20217:00 amRNSCommercial momentum in ImmunoINSIGHTS
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 202110:36 amRNSResults of Annual General Meeting
3rd Nov 20217:00 amRNSNotice of AGM and posting of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.